



# Trojan Ethical Income Fund


All data as at 31 July 2018


www.taml.co.uk

The investment objective of the Trojan Ethical Income Fund is to provide income with the potential for capital growth in the medium term. Its investment policy is to invest substantially in UK and overseas equities. Trojan Ethical Income Fund may also invest in fixed interest securities, indices, deposits, collective investment schemes and money market instruments. The Fund will invest in accordance with the parameters of its ethical investment criteria. Any comparisons against indices are for illustrative purposes only.

**Prices** 121.55p 114.32p 'O' accumulation shares 'O' income shares

**Dividend Yield Fund Size** 3.0% £88m 'O' income shares





Total Return to 31 July 2018	06/01/16 Since launch	31/07/17 1 year	31/01/18 6 months
Trojan Ethical Income Fund O Acc	+21.6%	+6.0%	+3.3%
LIBID GBP 1 Month*	+0.7%	+0.3%	+0.2%
FTSE All-Share Index (TR)+	+39.6%	+9.2%	+5.0%

Discrete Calendar Annual Returns	2016#	2017	2018 YTD
Trojan Ethical Income Fund O Acc	+8.0%	+10.2%	+2.1%

<sup>\*</sup>London Inter Bank Bid Rate

Past performance is not a guide to future performance

Source: Lipper

## July Commentary

Your Fund produced a return of +2.0% during substantially less of its sales, particularly in particular in oncology. They are now on the All-Share Index (TR).

July was a busy month with 21 of our holdings reporting their half-yearly earnings. We were encouraged to see renewed strength in our core consumer-centric companies, some of of Reckitts,

the month, compared to +1.3% for the FTSE China, come from e-commerce. However, a cusp of offsetting lost sales from older off-JD.com to facilitate the supply of infant plenty of expansion to come. formula to emerging urban areas in China should prove a significant boost to this

sentiment earlier in the year. This included holdings, including the UK pharma titans priced, with no premium), which will some early signs of Reckitt Benckiser (+9%) AstraZeneca (+12%) and GlaxoSmithKline strengthen cash flows and support the reaping rewards from its acquisition of baby (+3%). We have been patient holders of Astra dividend. While much of GSK's pipeline is formula maker Mead Johnson last year. Infant through its multi-year reinvigoration of its less developed than Astra's, the company has nutrition is an attractive market with obvious R&D and drug pipeline. We are finally seeing exciting new growth drivers; for example, tailwinds, but Mead Johnson also has other these efforts bear fruit, with the company their recently launched shingles vaccine, growth levers to pull. Compared with the rest rightly receiving recognition for its newly Shingrix, is without a worthy competitor and developed world-class treatments, in experiencing huge demand.

new partnership with internet retail giant patent drugs with new ones, and there is

At GSK, CEO Emma Walmsley has brought sweeping changes, including poaching a new head of pharma from Astra and buying out which had been dented by negative It was also a good month for our Healthcare Novartis' stake in their consumer JV (sensibly

<sup>&</sup>lt;sup>#</sup>from 6 January 2016

<sup>\*©</sup> FTSE International Limited 2018.

### **Ethical Investment Criteria**

Trojan Ethical Income Fund will invest based on specific ethical investment criteria as well as adhering to Troy's fundamental stock selection process. For inclusion in the Fund's investible universe, potential investments will be screened against ethical investment criteria using a combination of third party data and the Investment Manager's primary research. The present ethical investment criteria mean that the Fund will not invest in any organisation which:

**Tobacco** – makes more than 10% of its total turnover from tobacco products.

Pornography - derives more than 3% of its total turnover from pornography or adult entertainment.

Fossil Fuels – (a) derives more than 33% of its total turnover from the refining or extraction of, or generation of power from, fossil fuels and/ or (b) derives more than 10% of its turnover from coal mining activities. Companies whose listing falls within Oil & Gas sector are also excluded.

Armaments – (a) generates more than 10% of its total turnover from strategic military supplies relating to conventional weapons and/or (b) produces key parts of, or provides services for, cluster munitions systems, and/or (c) is alleged to have contravened the convention on antipersonnel mines in the last ten years and which has not addressed the allegations, and/ or (d) manufactures products, or provides services, which are all or part of a nuclear weapons system.

Alcohol – derives more than 10% of its total turnover from the sale or production of alcohol.

Gambling - derives more than 10% of its total turnover from gambling (including spread betting).

High Interest Rate Lending – derives more than 25% of its total turnover from high interest rate lending (high interest being defined as lending at an annual percentage rate (APR) of over

Top 10 holdings	% Fund
Unilever	5.4
GlaxoSmithKline	4.3
Reckitt Benckiser	4.1
Nestlé	3.7
Compass	3.5
Lloyds	3.3
Experian	3.1
Procter & Gamble	3.0
RELX	3.0
American Express	2.5
Total Top 10	35.9
34 other holdings	50.4
Cash & Equivalent	13.7
Total	100.0

Holdings subject to change

Dealing

Source: Troy Asset Management Limited

#### **Fund information**

A copy of the latest Prospectus and the KIID for each class (in English) upon which you should base your investment decision is available from Link Fund Solutions Ltd, the Fund's Authorised Corporate Director and Link Fund Administrators Ltd (Authorised and Regulated by the Financial Conduct Authority) on 0345 608 0950.

**Ongoing Charges** 

Structure Sub-fund of Trojan Inve UCITS	estment Funds
Investment Adviser Troy Asset Manageme 33 Davies Street London W1K 4BP Tel: 020 7499 4030 Fax: 020 7491 2445 email: busdev@taml.co	
Fund Manager	Hugo Ure
Currency	£ Sterling
Launch Date	06 January 2016

'O' (ordinary) shares: 'S' (charity) shares:	1.15% 0.90%
Dividend Ex Dates 1 August (interim), 1 February (final)	
Dividend Pay Dates 30 September (interim), 31 March (final)	
B I. 120 II	
Dividend Yield	3.01%
Authorised Corporate Director Link Fund Solutions Limited Tel: 0345 300 2110	3.01%

GB00BYMLFR07 (S Inc), GB00BYMLFQ99 (S Acc)

Daily at noon Tel: 0345 608 0950 Registrar Link Fund Administrators Limited Auditor Ernst & Young LLP Depositary The Bank of New York Mellon (International) Limited Bloomberg (O shares)

TEIFOAC\_LN (O Acc), TEIFOIN\_LN (O Inc)

SEDOL (O shares) BYMLFK3 (O Acc), BYMLFL4 (O Inc)

Pricing "O" share class prices published daily in the FT

Important Information
Fund performance data provided is calculated net of fees unless stated otherwise. Past performance is not a guide to future performance. All references to benchmarks are for comparative purposes only. Overseas investments may be affected by movements in currency exchange rates. The value of an investment and any income from it may fall as well as rise and investors may get back less than they invested. Neither the views nor the information contained within this document constitute investment advice or an offer to invest or to provide discretionary investment management services and should not be used as the basis of any investment decision. Any decision to invest should be based on information contained in the prospectus, the relevant key investor information document and the latest report and accounts. The investment policy and process of the fund(s) may not be suitable for all investors. If you are in any doubt about whether the fund(s) is/are suitable for you, please contact a professional adviser. References to specific securities are included for the purposes of illustration only and should not be construed as a recommendation to buy or sell these securities. Although Troy Asset Management Limited considers the information included in this document to be reliable, no warranty is given as to its accuracy or completeness. The opinions expressed are expressed at the date of this document and, whilst the opinions stated are honestly held, they are not guarantees and should not be relied upon and may be subject to change without notice. Third party data is provided without warranty or liability and may belong to a third party. The fund(s) is/are registered for distribution to the public in the UK and Ireland but not in any other jurisdiction. The distribution of shares of Trojan Investment Fund ("Shares") in Switzerland, as made exclusively to, audilied investors ("Qualified investors"), as defined in the Swiss Collective Investment Schemes Act of 23 June 2006, as amended, and its implemen Copyright Troy Asset Management Limited 2018